May 21, 2025

Birth Control Pills Triple Stroke Risk?

New SECRETO study reveals combined oral contraceptives increase cryptogenic ischemic stroke risk threefold in women aged 18 to 49, independent of other known risk factors.

Conexiant

May 20, 2025

Clinical Trials Missing in Half of AI Tools

Researchers analyzed FDA-approved AI-enabled medical devices and reported that clinical performance and subgroup data were frequently missing.

Conexiant

May 19, 2025

No-Touch Technique May Improve CABG Graft Outcomes

A large study of 2,655 CABG patients found that using the no-touch technique to harvest vein grafts significantly reduced blockage, heart attacks, and repeat procedures over three years.

Conexiant

May 19, 2025

CAA Imaging Markers Linked to Plasma Biomarkers

A large cohort study in South Korea found that cerebral amyloid angiopathy imaging markers were linked to increased Alzheimer’s-related plasma biomarkers and cognitive decline, partly mediated by brain amyloid buildup.

Conexiant

May 15, 2025

Chikungunya Vaccine Linked to Adverse Events

The FDA and CDC have paused use of the Ixchiq chikungunya vaccine in adults aged 60 and older due to reports of serious postmarketing adverse events.

Conexiant

May 05, 2025

New Chikungunya Vaccine Shows Strong Response

A new single-dose chikungunya vaccine produced strong immune responses in nearly all adolescents and adults in a large clinical trial, with mild and short-lived side effects.

Conexiant

May 01, 2025

Phthalates Linked to Cardiovascular Mortality Globally

Researchers linked di-2-ethylhexylphthalate plastic exposure to over 350,000 cardiovascular deaths and 10 million years of life lost, supporting calls for international regulatory measures.

Conexiant

April 30, 2025

New Phase III Data: Sotatercept for PAH

Sotatercept reduced the composite risk of death, lung transplantation, or hospitalization for worsening pulmonary arterial hypertension by nearly 75% compared with placebo in high-risk patients in a phase III trial.

Conexiant

April 29, 2025

New Oral Option Approved for GCA

The FDA approved Rinvoq (upadacitinib) as the first and only oral Janus kinase inhibitor for the treatment of giant cell arteritis in adults, providing a steroid-sparing option for achieving sustained remission.

Conexiant